PHARMIG s.r.o.Active
Key figures
Key figures
2025Dividends
calculatedDistributed as dividends 10 001 € (4 % of distributable profit).
Balance sheet structure
Summary of annual reports2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue (net turnover) | 0 | 0 | 0 | 0 | 0 |
| Profit for the reporting year | 48 049 | 32 200 | 71 782 | 64 079 | 32 934 |
| Retained earnings of previous periods | 89 713 | 137 762 | 107 862 | 178 986 | 233 064 |
| Total assets | 548 904 | 589 179 | 702 240 | 779 156 | 847 210 |
| Total liabilities | 405 642 | 413 717 | 517 096 | 530 591 | 575 712 |
| Total equity | 143 262 | 175 462 | 185 144 | 248 565 | 271 498 |
| Calculated dividends | 0 | 0 | 62 100 | 658 | 10 001 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Similar companies
Summary: PHARMIG s.r.o.
Overview
PHARMIG s.r.o. (IČO 47799170) is a limited liability company (s.r.o.). The company was incorporated in 2014 and has existed for 12 years. Registered office according to the register: Košice-Šaca. Main activity according to the Statistical Office: ostatné pomocné obchodné činnosti i. n. (SK NACE 8299). Size category by number of employees: 3–4 employees.
People
The statutory body has 2 members. According to the register, the company has 2 shareholders. The registered capital is 5 000 €.
Financial results
The company reported no revenue in 2025. Net profit for 2025 was 32 934 €. The company was profitable in all 6 reported years. Personnel costs for 2025 were 117 540 €. At the end of 2025 the company had total assets of 847 210 € and equity of 271 498 € (equity ratio 32,0 %).
Sources and freshness
Company and people data come from the Register of Legal Entities (Statistical Office SR, CC BY 4.0) and financial statements from the Register of Financial Statements (Ministry of Finance SR); icoprofil.sk updates them daily. Data as of 9. 11. 2026. Changes, averages and ratios are calculated by icoprofil.sk from open data and are not an official assessment.